A coronavirus vaccine has been used since the previous epidemic in 2003.

We are now fighting version 2 of the virus since then.

Companies have been working to create vaccines to attack coronaviruses since 2003, and claims that the vaccine was made very quickly and that it would pose risks to human life and health are false.

This was stated by the Minister of Health, Prof. Kostadin Angelov, at today’s Health Ministry briefing, recalling the 2002-2003 epidemic of severe acute respiratory syndrome, which was confined to southern parts of China. The cause of this syndrome is also a coronavirus, which scientists later named SARS-CoV.

“This year the name of the virus is SARS-CoV-2, so we can say that this is the second version of the coronavirus since 2003, if we can afford this kind of comparison. Since 2003, companies have been working to create a vaccine to attack coronavirus, so claims that this vaccine is manufactured very quickly and that it will present risks to human life and health are false, in addition, the vaccine passes all regulatory requirements necessary to ensure its safety, namely all phases of clinical trials and only then will the European Medicines Agency issue an opinion on the basis of which the European Commission will give an answer and a decision on whether it should be put into use in all European countries, “Angelov explained in response to people’s concerns about the safety of the vaccine we expect.

Drug safety monitoring does not end with the completion of the clinical trial, added the head of the Executive Agency for Medicines Bogdan Kirilov, who explained that study participants are subject to additional monitoring for at least 2 months to a year. year later.

“In general, most adverse reactions have been found to occur between 4 and 6 weeks after administration. In addition, once a marketing authorization has been authorized, drug safety surveillance is closely monitored. Any adverse reaction report is validated by national agencies and falls into a common database, which also provides in-depth analysis of this information so you can react very quickly if necessary, “Kirilov said.

Additionally, manufacturers are required to submit safety reports and risk management plans on a monthly basis.